Creating a Platform for Precise Anti-Cancer Medicine (Q4295268): Difference between revisions
Jump to navigation
Jump to search
(Created a new Item: Import item from Austria, Italy) |
(Changed label, description and/or aliases in en: Setting new description) |
||
| description / en | description / en | ||
Project Q4295268 in Austria, Italy | |||
Revision as of 15:26, 10 June 2022
Project Q4295268 in Austria, Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Creating a Platform for Precise Anti-Cancer Medicine |
Project Q4295268 in Austria, Italy |
Statements
998,629.26 Euro
0 references
1,294,139.55 Euro
0 references
77.17 percent
0 references
14 March 2016
0 references
2 August 2019
0 references
CONSORZIO INTERUNIVERSITARIO PER LE BIOTECNOLOGIE - LABORATORIO NAZIONALE
0 references
46°3'58.03"N, 13°13'59.02"E
0 references
45°39'29.09"N, 13°47'33.07"E
0 references
47°15'46.73"N, 11°23'3.91"E
0 references
47°15'40.57"N, 11°22'59.95"E
0 references
45°39'30.78"N, 13°47'35.66"E
0 references
Therapeutic strategies that are based on the individual genetic profile of a patient represent a new frontier of applied cancer research. These strategies are expected to reduce the socio-economic impact of current cancer therapies that are cost-intensive and often ineffective, thus releasing pressure on regional health systems. In this context, tumor-organoids are of special relevance. Tumor-organoids are three-dimensional cellular complexes that are cultivated in vitro from cells that were previously obtained from patient tumors or biopsies. Tumor-organoids have the special property to mirror the key-features of the original patient’s tumor. Thus, Tumor-organoids represent an ideal tool to develop patient-specific therapies by performing drug-screenings. The PreCanMed project aims to strengthen the collaboration between Italian and Austrian institutions that perform genetic, clinical and biotechnology research in order to establish a common competence-platform for the generation, cultivation and storage (Live-biobank) of numerous patient-derived Tumor-organoids. Tumor-organoids and know-how will be freely accessible, thus making this cutting edge technology accessible to the academic, translational, clinical and pharmaceutical research and development sector. (English)
0 references